SOBI
BUY
Conviction: 3/5
$8B
Swedish Orphan Biovitrum AB
Investment Thesis
Rare disease specialist with diversified portfolio across hematology and immunology. Multiple near-term catalysts: NASP PDUFA June 2026 (uncontrolled gout), Altuvoct hemophilia A launch ramp crushing estimates, Doptelet ITP franchise expansion, Beyfortus royalty escalation (25%->35%). Stock up ~44% in 6 months on execution and pipeline de-risking. FY2025 rev SEK 28.2B (+15% CER), adj EBITA margin 40%. 2026 guidance: low double-digit CER growth.
Bull Case
NASP approved (PDUFA Jun 2026) and captures significant share from Krystexxa in $2B+ uncontrolled gout market. Altuvoct becomes dominant hemophilia A factor, reaching SEK 5B+. Beyfortus royalty escalates to 35% on $3B+ US sales. Pozdeutinurad Phase 3 data positive, opening $10B+ broader gout market. Gamifant platform expands into sepsis (massive addressable market). Multiple pipeline readouts create re-rating catalysts through 2027.
Bear Case
NASP gets CRL from FDA (immunogenicity concerns or ADA rates). Altuvoct launch stalls as non-factor therapies (Hemlibra, denecimig) dominate. Vonjo loses accelerated approval if PACIFICA fails (FDA withdrawal risk). Zynlonta LOTIS-5 fails to confirm accelerated approval. Beyfortus seasonality worse than expected. Margin compression in 2026 transition year disappoints.
Drug Portfolio (15)
Immunology
Biologic (enzyme + nanoparticle)
IV
Immunology
Small molecule
PO
Hematology
Small molecule
PO
Hematology
Antibody-drug conjugate
IV
Immunology
Monoclonal antibody
IV
Hematology
Small molecule
PO
Immunology
Monoclonal antibody
IM
Hematology
Recombinant protein
IV
Hematology
PEGylated peptide
SC
CVRM
Antisense oligonucleotide
SC
| Drug | Stage | Role | Ownership | Area | Modality |
|---|
| Elocta | APPROVED | LICENSEE | 50% | Hematology | Recombinant protein |
| Alprolix | APPROVED | LICENSEE | 50% | Hematology | Recombinant protein |
| Kineret | APPROVED | ORIGINATOR | 100% | Immunology | Recombinant protein |
| Orfadin | APPROVED | ORIGINATOR | 100% | Rare Disease | Small molecule |
| Rytelo | APPROVED | LICENSEE | 0% | Hematology | Oligonucleotide |
Catalysts (13)
SOBI - Capital Markets Day (Ambition 2030)
GUIDANCE
SM
SOBI IR website, CMD invitation (sobi.com/investors)
February 18, 2026
Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-2)
CLINICAL
SM
SOBI Q4 2025 Report; Arthrosi acquisition press release
Q2 2026
Zynlonta - R/R DLBCL 2L - Ph3 - Data (LOTIS-5)
CLINICAL
SM
SOBI Pipeline page; ClinicalTrials.gov
H1/H2 2026
Beyfortus - RSV Royalty Revenue Trajectory (vs Enflonsia)
COMMERCIAL
SM
SOBI Q4 2025 Report; CDC RSVVaxView; Merck Enflonsia approval
Quarterly through 2026
Altuviiio - Hemophilia A Commercial Ramp (EU/Middle East)
COMMERCIAL
SM
SOBI Q4 2025 Report
Quarterly through 2026-2027
SOBI - Q1 2026 Earnings
GUIDANCE
SOBI typical earnings calendar
Late April / Early May 2026
Rytelo - Lower-risk MDS - EU Country-by-Country Launch
COMMERCIAL
SOBI Q4 2025 Report
Throughout 2026
Doptelet - Pediatric ITP + EU Expansion - Ongoing
COMMERCIAL
SOBI Q4 2025 Report
H1 2026
NASP - Uncontrolled Gout - FDA PDUFA Decision
REGULATORY
SM
FDA PDUFA date per SOBI Q4 2025 Report
June 27, 2026
Vonjo - MF (severe thrombocytopenia) - Ph3 - Confirmatory (PACIFICA)
CLINICAL
SM
FDA post-marketing requirement; SOBI Pipeline page
2026-2027
Gamifant - IFN-gamma-driven Sepsis - Ph2b/3 Design Discussion
CLINICAL
SOBI Q4 2025 Report; EMBRACE Phase 2a topline Jan 7, 2026
2026
Tryngolza - Severe Hypertriglyceridemia - EMA Submission
REGULATORY
SOBI Q4 2025 Report; Ionis pipeline updates
2026
Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-1)
CLINICAL
SM
SOBI Q4 2025 Report
Q4 2026
Data from Supabase · Updated 2026-03-24